Treatment with miglustat reverses the lipid-trafficking defect in Niemann–Pick disease type C
Open accessThe DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Abstract
Niemann-Pick disease type C (NP-C) is a hereditary neurovisceral lipid storage disorder. Although traditionally considered a primary cholesterol storage disorder, a variety of glycolipids accumulate in NP-C cells, which resemble those from glycosphingolipidosis patients. Substrate reduction therapy (SRT) with miglustat, an inhibitor of glycosphingolipid biosynthesis, is a novel therapy for the glycosphingolipidoses. We report the use of SRT in a patient with NP-C. We show that depletion of glycosphingolipids by miglustat treatment reduces pathological lipid storage, improves endosomal uptake and normalises lipid trafficking in peripheral blood B lymphocytes. The demonstration that treatment with miglustat, which has no direct effect on cholesterol metabolism, corrects the abnormal lipid trafficking seen in B lymphocytes in NP-C indicates that glycosphingolipid accumulation is the primary pathogenetic event in NP-C. These observations support the use of SRT in patients with this devastating neurodegenerative disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Marked elevation of plasma chitotriosidase activity. A novel hallmark of Gaucher disease.
Hollak, C. E., van Weely, S., van Oers, M. H., & Aerts, J. M. (1994) · Journal of Clinical Investigation · doi:10.1172/jci117084 · Cited by 896
Vanier, M., & Millat, G. (2003) · Clinical Genetics · doi:10.1034/j.1399-0004.2003.00147.x · Cited by 578 · cited 2×
“Keywords: Niemann–Pick disease type C; Substrate reduction therapy; Miglustat; Glycosphingolipidoses; Lipid trafficking Introduction Niemann–Pick disease type C (NP-C) is a hereditary neurovisceral lipid storage disorder (Vanier and Millat, 2003).”
Puri, V., Jefferson, J. R., Singh, R. D., Wheatley, C. L., Marks, D. L., & Pagano, R. E. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m300304200 · Cited by 89
Cited by
Lloyd-Evans, E., Morgan, A. J., He, X., Smith, D. A., Elliot-Smith, E., Sillence, D. J., Churchill, G. C., Schuchman, E. H., Galione, A., & Platt, F. M. (2008) · Nature Medicine · doi:10.1038/nm.1876 · Cited by 829
Self-citationPastores, G. M. (2012) · Swaiman's Pediatric Neurology · doi:10.1016/b978-1-4377-0435-8.00036-6 · Cited by 633
Miglustat for treatment of Niemann-Pick C disease: a randomised controlled study
Patterson, M. C., Vecchio, D., Prady, H., Abel, L., & Wraith, J. E. (2007) · The Lancet Neurology · doi:10.1016/s1474-4422(07)70194-1 · Cited by 608
Recommendations for the diagnosis and management of Niemann–Pick disease type C: An update
Patterson, M. C., Hendriksz, C. J., Walterfang, M., Sedel, F., Vanier, M. T., & Wijburg, F. (2012) · Molecular Genetics and Metabolism · doi:10.1016/j.ymgme.2012.03.012 · Cited by 475
The adult form of Niemann-Pick disease type C
Sevin, M., Lesca, G., Baumann, N., Millat, G., Lyon-Caen, O., Vanier, M. T., & Sedel, F. (2006) · Brain · doi:10.1093/brain/awl260 · Cited by 387
Vellodi, A. (2005) · British Journal of Haematology · doi:10.1111/j.1365-2141.2004.05293.x · Cited by 295
Mechanisms for cellular cholesterol transport: Defects and human disease
Ikonen, E. (2006) · Physiological Reviews · doi:10.1152/physrev.00022.2005 · Cited by 229
“Interestingly, studies in yeast reveal a role for NPC1 in the recycling of sphingolipids (140), and in human subjects, sphingolipids are more promising than cholesterol as targets for therapies aiming at substrate reduction (122).”
BackgroundPharmacological Chaperones as Therapeutics for Lysosomal Storage Diseases
Boyd, R. E., Lee, G., Rybczynski, P., Benjamin, E. R., Khanna, R., Wustman, B. A., & Valenzano, K. J. (2013) · Journal of Medicinal Chemistry · doi:10.1021/jm301557k · Cited by 209
Saturation variant interpretation using CRISPR prime editing
Erwood, S., Bily, T. M. I., Lequyer, J., Yan, J., Gulati, N., Brewer, R. A., Zhou, L., Pelletier, L., Ivakine, E. A., & Cohn, R. D. (2022) · Nature Biotechnology · doi:10.1038/s41587-021-01201-1 · Cited by 163
Sensitivity to Lysosome-Dependent Cell Death Is Directly Regulated by Lysosomal Cholesterol Content
Appelqvist, H., Sandin, L., Björnström, K., Saftig, P., Garner, B., Öllinger, K., & Kågedal, K. (2012) · PLoS ONE · doi:10.1371/journal.pone.0050262 · Cited by 108
“, by decreasing cholesterol levels [10], inhibiting glycosphingolipid synthesis [11] or increasing lipid”
BackgroundRelative acidic compartment volume as a lysosomal storage disorder–associated biomarker
te Vruchte, D., Speak, A. O., Wallom, K. L., Al Eisa, N., Smith, D. A., Hendriksz, C. J., Simmons, L., Lachmann, R. H., Cousins, A., Hartung, R., et al. (2014) · Journal of Clinical Investigation · doi:10.1172/jci72835 · Cited by 73
Self-citationCabrera-Reyes, F., Parra-Ruiz, C., Yuseff, M. I., & Zanlungo, S. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.790568 · Cited by 24
Li, R., Hao, J., Fujiwara, H., Xu, M., Yang, S., Dai, S., Long, Y., Swaroop, M., Li, C., Vu, M., et al. (2017) · ASSAY and Drug Development Technologies · doi:10.1089/adt.2017.774 · Cited by 21
Metadata
- Authors
- Lachmann, R. H., te Vruchte, D., Lloyd-Evans, E., Reinkensmeier, G., Sillence, D. J., Fernandez-Guillen, L., Dwek, R. A., Butters, T. D., Cox, T. M., & Platt, F. M.
- Venue
- Neurobiology of Disease
- Publisher
- Elsevier BV
- Published
- 2004-08
- Volume
- 16
- Issue
- 3
- Pages
- 654-658
- ISSN
- 0969-9961 (ISSN-L)
- OpenAlex
- W2032170216
- Cited by
- 150
- References
- 3
- FWCI
- 6.27
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.